| AME |
Report |
Adjusted EPS |
BEAT |
pred ~$2.02 vs. cons $2.00 |
MEDIUM |
| AME |
Report |
Net sales |
BEAT |
pred ~$1.980B vs. cons $1.959B |
MEDIUM |
| AME |
Report |
Organic growth |
BEAT |
pred ~5.5% vs. cons 5.03% |
MEDIUM |
| AME |
Guide |
Q3 revenue |
BETTER |
guide ~high-single-digit growth / $2.05B vs. cons $2.021B |
MEDIUM |
| AME |
Guide |
Q3 adjusted EPS |
UNCHANGED |
guide ~$2.02-$2.06 vs. cons $2.05 |
MEDIUM |
| AME |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$8.12-$8.22 vs. cons $8.16 |
MEDIUM |
| AME |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| AME |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — modest FY raise validates estimates |
MEDIUM |